On Monday, January 27, the next meeting of the AOTMiT Transparency Council.
Agenda:
- Preparation of an opinion on the continuation of reimbursement in off-label indications
- Medicinal products containing the active substance bevacizumab for the treatment of CRVO and BRVO (central retinal vein and branch vein thrombosis) under drug program B.70 "Treatment of patients with retinal diseases" (ICD-10: H35.3, H36.0).
- Preparation of a position paper on the evaluation of the drug Keytruda (pembrolizumabum)
- Drug program B.141.FM:...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
- Drug program B.141.FM:...
